Q-omics provides the consensus-scored RPL12P41 profile across patient tissues and cancer cell-line models. RPL12P41 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPL12P41 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, RPL12P41 RNA expression shows 7,418 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, COAD, and BRCA as cancer lineages where RPL12P41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL12P41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL12P41 survival associations across molecular data types. RPL12P41 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL12P41 RNA expression–survival associations across cancer types. High RPL12P41 expression shows unfavorable associations in ACC, but favorable associations in MESO, LGG, CESC, HNSC and LUSC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for RPL12P41 RNA expression.
This table summarizes RPL12P41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL12P41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL12P41 shows higher tumor expression in COAD, KIRP, KIRC, LUAD, LUSC and THCA. The COAD box plot shows higher RPL12P41 RNA expression in tumor versus normal tissue (log2 FC = +0.303, t-test p < 0.001).
This table shows molecular features associated with RPL12P41 in patient tissues and cancer cell lines. In patient samples, RPL12P41 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
